Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA

Braidwell LP lowered its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 9.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,382,350 shares of the company’s stock after selling 142,492 shares during the quarter. Braidwell LP’s holdings in Oruka Therapeutics were worth $26,583,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in Oruka Therapeutics in the 2nd quarter worth $28,000. Ameritas Investment Partners Inc. purchased a new stake in Oruka Therapeutics during the second quarter valued at about $31,000. BNP Paribas Financial Markets boosted its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics during the third quarter valued at about $39,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Oruka Therapeutics during the third quarter valued at about $43,000. Institutional investors own 56.44% of the company’s stock.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Insiders Place Their Bets

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the sale, the insider directly owned 34,018 shares in the company, valued at approximately $1,101,162.66. This trade represents a 17.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 21,000 shares of company stock valued at $663,530. Company insiders own 24.69% of the company’s stock.

Wall Street Analysts Forecast Growth

ORKA has been the subject of a number of recent research reports. UBS Group initiated coverage on Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price for the company. Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday. BTIG Research reaffirmed a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a research note on Friday. Piper Sandler started coverage on Oruka Therapeutics in a research report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective for the company. Finally, Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Trading Up 25.0%

Oruka Therapeutics stock opened at $40.00 on Friday. The firm has a 50-day moving average of $32.92 and a 200-day moving average of $27.59. The firm has a market cap of $1.94 billion, a P/E ratio of -21.51 and a beta of -0.38. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $41.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.16. Research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.